No connection

Search Results

TIVC

BEARISH
$1.13 Live
Tivic Health Systems, Inc. · NASDAQ
$0.72 52W Range $13.23

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 21, 2026
Market cap
$3.25M
P/E
N/A
ROE
-82.7%
Profit margin
N/A
Debt/Equity
0.38
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
TIVC exhibits severe financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. Despite a high current ratio suggesting short-term liquidity, the company is experiencing a catastrophic collapse in revenue (-267.78% Q/Q) and a near-total loss of shareholder value over a 5-year horizon (-100%). While the stock trades at a deep discount to book value (P/B 0.17), the lack of profitability and negative ROE (-82.69%) suggest a value trap rather than a value opportunity.

Key Strengths

Extremely high current ratio (20.13) indicating strong short-term liquidity
Low Debt/Equity ratio (0.38) relative to healthcare sector average
Recent quarterly earnings beats (though still deeply negative)
Trading significantly below book value (P/B 0.17)
Short-term price momentum (1-week change +24%)

Key Risks

Catastrophic Q/Q revenue decline of -267.78%
Severe long-term price erosion (99.5% loss over 3 years)
Critical Piotroski F-Score of 1/9 signaling fundamental failure
Negative ROE (-82.69%) and ROA (-28.69%)
Complete lack of analyst coverage and institutional guidance

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
8
Weak
Value
20
Future
5
Past
0
Health
15
Dividend
0
AI Verdict
Distressed Asset
Key drivers: Piotroski F-Score 1/9, Revenue collapse, Long-term price decay
Confidence
90%
Value
20/100

P/B is low, but lack of earnings makes traditional valuation formulas inapplicable.

Positives
  • Very low Price-to-Book ratio (0.17)
Watchpoints
  • No positive earnings to support Graham Number
  • Negative forward P/E
Future
5/100

Q/Q Revenue Growth is -267.78%.

Positives
  • Recent short-term price bounce
Watchpoints
  • Extreme negative revenue growth
  • No clear path to profitability
Past
0/100

Historical price performance is catastrophic.

Positives
No standout positives identified.
Watchpoints
  • 5-year change of -100%
  • Consistent negative earnings
Health
15/100

High liquidity is the only saving grace, but operational health is failing.

Positives
  • High liquidity (Current Ratio 20.13)
  • Low leverage
Watchpoints
  • Piotroski F-Score 1/9
  • Negative ROE/ROA
Dividend
0/100

Dividend Strength 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.13

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TIVC and closest competitors.

Updated 2026-04-20
TIV
Tivic Health Systems, Inc.
Primary
5Y
-100.0%
3Y
-99.5%
1Y
-67.7%
6M
-60.4%
1M
+22.8%
1W
+24.0%
NUW
Nuwellis, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-96.9%
6M
-64.7%
1M
+3.8%
1W
+13.4%
MND
Mobile-health Network Solutions
Peer
5Y
-99.7%
3Y
-99.7%
1Y
-89.1%
6M
-76.7%
1M
-0.3%
1W
-3.9%
ACO
Aclarion, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-82.0%
6M
-56.9%
1M
+22.9%
1W
+1.8%
HCT
Healthcare Triangle, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-99.9%
6M
-98.6%
1M
-21.6%
1W
-2.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-0.05
PEG Ratio
N/A
P/B Ratio
0.17
P/S Ratio
N/A
EV/Revenue
N/A
EV/EBITDA
0.37
Market Cap
$3.25M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin N/A
Gross Margin N/A
ROE -82.69%
ROA -28.69%

Growth

Revenue and earnings growth rates

Revenue Growth N/A
Earnings Growth N/A
Q/Q Revenue Growth -267.78%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.38
Low debt
Current Ratio
20.13
Strong
Quick Ratio
19.57
Excellent
Cash/Share
$4.39

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$-0.0B
Op. Margin
654.0%
Net Margin
943.4%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.88x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%

Quarterly Earnings History

EPS performance vs analyst estimates

2023-11-14
$-25.16
+78.9% surprise
2023-08-14
$-119.0
+12.5% surprise
2023-05-15
$-187.0
2023-03-31
$-391.0
+25.8% surprise

Healthcare Sector Comparison

Comparing TIVC against 498 companies in the Healthcare sector (28 bullish, 153 neutral, 317 bearish)
Return on Equity (ROE)
-82.69%
This Stock
vs
-95.47%
Sector Avg
-13.4% (Below Avg)
Debt to Equity
0.38
This Stock
vs
2.89
Sector Avg
-86.7% (Less Debt)
Current Ratio
20.13
This Stock
vs
4.66
Sector Avg
+331.9% (Stronger)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

VALAURI CHRISTINA RIZOPOULOS
Director
Buy
2026-04-01
19,000 shares · $18,008
WOLF LISA G
Chief Financial Officer
Stock Award
2026-03-18
92 shares
HANDLEY MICHAEL K
Chief Operating Officer
Stock Award
2026-02-18
8,824 shares
WOLF LISA G
Chief Financial Officer
Stock Award
2025-12-18
736 shares
ERNST JENNIFER
Chief Executive Officer
Stock Award
2025-12-18
14,706 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

S-1
FORM S-1
2026-04-13

TIVC filed a Form S-1 on April 13, 2026, to register securities in preparation for an initial public offering.

10-K
FORM 10-K
2026-03-30

TIVC filed its annual Form 10-K on March 30, 2026. Specific financial highlights and risk factors were not provided in the available metadata.

8-K
FORM 8-K
2026-03-25
8-K
FORM 8-K
2026-03-20
8-K
CURRENT REPORT
2026-03-13
8-K
FORM 8-K
2026-03-11
8-K
CURRENT REPORT
2026-03-04
8-K/A
FORM 8-K AMENDMENT
2026-02-23

Tivic Health Systems, Inc. filed an amendment to a previously submitted Form 8-K.

8-K
FORM 8-K
2026-02-09
8-K
CURRENT REPORT
2026-01-20
DEF 14A
DEF 14A
2026-01-09
8-K
CURRENT REPORT
2025-12-11
8-K
FORM 8-K
2025-11-18
8-K
FORM 8-K
2025-11-14
10-Q
FORM 10-Q
2025-11-14
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning TIVC from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile